apixaban (Q414462)

Apixaban (English)

19 November 2016

COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N

1 reference

https://www.whocc.no/atc_ddd_index/?code=B01AF02

Apixaban (English)

19 November 2016

10 milligram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

apixaban (English)

1 reference

apixaban (English)

medical condition treated

19 October 2016

thrombosis

1 reference

2 October 2018

pulmonary embolism

1 reference

2 October 2018

atrial flutter

1 reference

2 October 2018

atrial fibrillation

1 reference

2 October 2018

heart disease

1 reference

significant drug interaction

2 October 2018

enoxaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dalteparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

urokinase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tinzaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rac-warfarin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fondaparinux

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alteplase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

heparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acenocoumarol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenindione

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenecteplase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Streptokinase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clopidogrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eptifibatide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

iloprost

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prostacyclin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tirofiban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prasugrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vortioxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibrutinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cangrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

abciximab

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(S)-duloxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

paroxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sertraline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

venlafaxine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluvoxamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ticagrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

6390

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

17 August 2016

legal status (medicine)

boxed warning

1 reference

reference URL

LiverTox likelihood score

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

LiverTox toxicity likelihood category D

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Apixaban

last update

9 February 2018

mass

459.191 dalton

1 reference

InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)

Apixaban (English)

19 October 2016

1 reference

5 March 2018

1 reference

Medical Subject Headings

15 March 2018

Apixaban

0 references

Identifiers

InChI

1 reference

Apixaban (English)

19 November 2016

2 references

Apixaban (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

503612-47-3

2 references

apixaban (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=503612-47-3

9 April 2021

1 reference

Apixaban (English)

19 November 2016

2 references

Apixaban (English)

19 November 2016

Reaxys registry number

11244786

1 reference

apixaban (English)

19 October 2016

mapping relation type

2 references

APIXABAN (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)

1 reference

APIXABAN (English)

19 November 2016

2 references

inferred from InChIKey

splash10-03di-0210900000-941cd1e773f20ff3a0d7

1 reference

0 references

HSDB ID

8223

1 reference

Hazardous Substances Data Bank

28 October 2019

Apixaban (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.167.332

27 December 2018

ECHA Substance Infocard ID

1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide (English)

quotation

CAS no.: 503612-47-3 (English)

100.167.332

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.167.332

27 December 2018

1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide (English)

quotation

CAS no.: 503612-47-3 (English)

1 reference

Guide to Pharmacology Ligand ID

Apixaban (English)

publication date

17 November 2015

6390

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

6390

apixaban (English)

19 November 2016

1 reference

Medical Subject Headings

14 March 2018

1 reference

apixaban (English)

19 November 2016

1 reference

Human Metabolome Database ID

HMDB0248515

2 references

based on heuristic

inferred from InChIKey

2 references

apixaban (English)

19 November 2016

MedlinePlus drug identifier

0 references

1 reference

apixaban (English)

19 November 2016

0 references

1 reference

1 reference

electronic Essential Medicines List medicine ID

apixaban (English)

19 October 2016

0 references

0 references

1 reference

28 October 2013

Microsoft Academic ID (discontinued)

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

2P16 (English)

19 October 2016

1 reference

1 reference